CDA | Evidence Driven
CDA | Evidence Driven

mepolizumab

Details

Files
Generic Name:
mepolizumab
Project Status:
Active
Therapeutic Area:
Eosinophilic Granulomatosis with Polyangiitis
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0839-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received19-Dec-23
Draft recommendation posted for stakeholder feedback1-Aug-24
End of feedback period16-Aug-24

Files

Draft Recommendation and Reasons View PDF
Proposed Project Scope View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Stakeholder Input View PDF

Related Content

Last Updated : September 11, 2024